Dr. Katherine Harris is Chief Development Officer at Rondo Therapeutics, where she leads all IND-enabling activities and is responsible for the design and execution of preclinical drug development from candidate nomination through IND submission. Previously, she was Vice President of Discovery at Amgen where she was instrumental in providing strategic and scientific direction for antibody therapeutics in Amgen’s Oncology portfolio. While at Amgen, she led integration of the acquired TeneoBio preclinical portfolio and sequence-based antibody discovery platform while serving as site head of the Amgen Newark Research Facility. As Vice President of Discovery at TeneoBio, Katherine built and led a highly successfully Oncology Research team, making key scientific and strategic contributions to clinical candidates that resulted in 4 IND approvals in less than 6 years of company operations. Prior to her work at TeneoBio and Amgen, she was a Research Scientist at Active Motif and SwitchGear Genomics where she focused her efforts on the development of a functional genomics platform for small molecule screening. Katherine holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She has presented in numerous national and international forums and has multiple peer-reviewed publications and issued patents.
You are here: / Katherine Harris, Ph.D.